
Errata

The September 10, 2016 article by Gounder et al, entitled “Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma,” (*Journal of Clinical Oncology* 34:3166-3174, 2016) was published with an error of omission.

The list of funders under the Research Funding header for author Albiruni Ryan Abdul Razak should have included NIH grant P30 CA008748. The list of funders was given as: “Merck, Karyopharm Therapeutics, Novartis, EntreMed, Pfizer,

MedImmune, Bristol-Myers Squibb, Genentech, Boston Biomedical, Boehringer Ingelheim.” Instead, it should have read as: “Merck, Karyopharm Therapeutics, Novartis, EntreMed, Pfizer, MedImmune, Bristol-Myers Squibb, Genentech, Boston Biomedical, Boehringer Ingelheim, **NIH Grant P30 CA008748.**”

The online version has been corrected in departure from the print. The authors regret the omission.

DOI: 10.1200/JCO.2016.72.5226; published March 1, 2017

The January 10, 2017 article by Fischer et al, entitled “Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma,” (*J Clin Oncol* 35:194-200, 2017) was published with an error.

Umberto Basso’s affiliation was given incorrectly as “Istituto di Ricovero e Cura a Carattere Scientifico, Padova,

Italy.” It should have been given as “**Umberto Basso, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.**”

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* apologizes for the error.

DOI: 10.1200/JCO.2016.72.4914; published March 1, 2017
